The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...
Background Intestinal fibrosis, a hallmark complication of Crohn’s disease (CD), frequently progresses to stricture formation ...
Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage ...
Plasma IQ is the latest advancement in aesthetics and the first FDA Class II cleared handheld plasma device. The device delivers focused, controlled plasma energy to safely and effectively create ...
TipRanks on MSN
FibroBiologics submits new patent application with USPTO
FibroBiologics (FBLG) announced that it has submitted a new patent application with the U.S. Patent and Trademark Office, USPTO, titled “Spheroids ...
The aggregate gross proceeds to the Company from the offering are expected to be approximately $1.7 million, before deducting placement agent’s fees and other offering expenses payable by the Company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback